Advertisement

Safety and Efficacy of Avelumab in Small Bowel Adenocarcinoma

Published:March 23, 2022DOI:https://doi.org/10.1016/j.clcc.2022.03.003

      Highlights

      • Avelumab is safe for patients with small bowel cancer.
      • Response rate was 29% and disease control rate was 71%.
      • Treatment was more effective in tumors with microsatellite instability.
      • Off-label use of immunotherapy and disease rarity contributed to slow accrual.
      • Immunotherapy with a companion biomarker should be explored in future trials.

      Abstract

      Introduction

      Small bowel adenocarcinomas (SBAs) are rare and frequently treated like large intestinal adenocarcinomas. However, SBAs have a very different microenvironment and could respond differently to the same therapies. Our previous data suggested that SBAs might benefit from targeting the PD-1/PD-L1 axis based on PD-L1 staining in almost 50% of SBA tissue samples tested. Thus, we designed a phase 2 study to explore safety and efficacy of avelumab in SBA.

      Patients and Methods

      Patients with advanced or metastatic disease were enrolled; ampullary tumors were considered part of the duodenum and allowed. Prior PD-1/PD-L1 inhibition was not allowed. Avelumab (10 mg/kg) was given every 2 weeks, and imaging was performed every 8 weeks. Primary endpoint was response rate.

      Results

      Eight patients (n = 5, small intestine; n = 3, ampullary) were enrolled, with a majority (88%) being male and a median age of 61 years. Of 7 efficacy-evaluable patients, 2 (29%) experienced partial responses; stable disease occurred in 3 additional patients (71%). Median progression-free survival was 3.35 months. Most frequent, related toxicities were anemia, fatigue, and infusion-related reaction (25% each), mostly grade ≤2; grade 3 hypokalemia and hyponatremia occurred in one patient, and another reported grade 4 diabetic ketoacidosis.

      Conclusions

      Despite the observed benefit, accrual was slower than expected and the study was closed early due to feasibility. A general clinic observation was that patients were receiving immunotherapy off-label as the availability of these agents increased. Off-label availability and disease rarity were likely drivers of insufficient accrual.

      Keywords

      Abbreviations:

      CIs (confidence intervals), CPS (combined positive score), SBA (small bowel adenocarcinoma)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Neugut AI
        • Jacobson JS
        • Suh S
        • Mukherjee R
        • Arber N
        The epidemiology of cancer of the small bowel.
        Cancer Epidemiol Biomarkers Prev. 1998; 7: 243-251
      1. National Cancer Institute. Surveillance, Epidemiology, and end results program. cancer stat facts: small intestine cancer. https://seer.cancer.gov/statfacts/html/smint.html; Accessed February 15 2021.

        • Siegel RL
        • Miller KD
        • Fuchs HE
        • Jemal A
        Cancer statistics, 2021.
        CA Cancer J Clin. 2021; 71: 7-33https://doi.org/10.3322/caac.21654
        • Reynolds I
        • Healy P
        • McNamara DA
        Malignant tumours of the small intestine.
        Surgeon. 2014; 12: 263-270https://doi.org/10.1016/j.surge.2014.02.003
        • Bakaeen FG
        • Murr MM
        • Sarr MG
        • et al.
        What prognostic factors are important in duodenal adenocarcinoma?.
        Arch Surg. 2000; 135 (discussion 641-2): 635-641
        • Raghav K
        • Overman MJ
        Small bowel adenocarcinomas–existing evidence and evolving paradigms.
        Nat Rev Clin Oncol. 2013; 10: 534-544https://doi.org/10.1038/nrclinonc.2013.132
        • Thota R
        • Gonzalez RS
        • Berlin J
        • Cardin DB
        • Shi C
        Could the PD-1 pathway be a potential target for treating small intestinal adenocarcinoma?.
        Am J Clin Pathol. 2017; 148: 208-214https://doi.org/10.1093/AJCP/AQX070
        • Pederson K
        • Smyrk TC
        • Harrington S
        e: Programmed death-ligand 1 (PD-L1) expression in small bowel adenocarcinomas (SBA).
        J Clin Oncol. 2015; 33 (suppl; abstr 3619)https://doi.org/10.1200/jco.2015.33.15_suppl.3619
        • Kaufman HL
        • Russell JS
        • Hamid O
        • et al.
        Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after >/=1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.
        J Immunother Cancer. 2018; 6: 7https://doi.org/10.1186/s40425-017-0310-x
        • Kaufman HL
        • Russell J
        • Hamid O
        • et al.
        Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
        Lancet Oncol. 2016; 17: 1374-1385https://doi.org/10.1016/S1470-2045(16)30364-3
        • Powles T
        • Park SH
        • Voog E
        • et al.
        Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma.
        N Engl J Med. 2020; 383: 1218-1230https://doi.org/10.1056/NEJMoa2002788
        • Apolo AB
        • Ellerton JA
        • Infante JR
        • et al.
        Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN solid tumor study: 2-year updated efficacy and safety analysis.
        J Immunother Cancer. 2020; 8https://doi.org/10.1136/jitc-2020-001246
        • Motzer RJ
        • Penkov K
        • Haanen J
        • et al.
        Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.
        N Engl J Med. 2019; 380: 1103-1115https://doi.org/10.1056/NEJMoa1816047
        • Schwartz LH
        • Litiere S
        • de Vries E
        • et al.
        RECIST 1.1-Update and clarification: from the RECIST committee.
        Eur J Cancer. 2016; 62: 132-137https://doi.org/10.1016/j.ejca.2016.03.081
        • Mizushima T
        • Tamagawa H
        • Mishima H
        • et al.
        The effects of chemotherapy on primary small bowel cancer: a retrospective multicenter observational study in Japan.
        Mol Clin Oncol. 2013; 1: 820-824https://doi.org/10.3892/mco.2013.150
        • Aparicio T
        • Zaanan A
        • Svrcek M
        • et al.
        Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment.
        Dig Liver Dis. 2014; 46: 97-104https://doi.org/10.1016/j.dld.2013.04.013
        • Weber J
        • Mandala M
        • Del Vecchio M
        • et al.
        Adjuvant Nivolumab versus ipilimumab in resected stage III or IV melanoma.
        N Engl J Med. 2017; 377: 1824-1835https://doi.org/10.1056/NEJMoa1709030
        • Reck M
        • Rodriguez-Abreu D
        • Robinson AG
        • et al.
        Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer.
        N Engl J Med. 2016; 375: 1823-1833https://doi.org/10.1056/NEJMoa1606774
        • Cortes J
        • Cescon DW
        • Rugo HS
        • et al.
        Investigators K-: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
        Lancet. 2020; 396: 1817-1828https://doi.org/10.1016/S0140-6736(20)32531-9
        • Fuchs CS
        • Doi T
        • Jang RW
        • et al.
        safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial.
        JAMA Oncol. 2018; 4e180013https://doi.org/10.1001/jamaoncol.2018.0013
        • Ferris RL
        • Blumenschein Jr., G
        • Fayette J
        • et al.
        Nivolumab for recurrent squamous-cell carcinoma of the head and neck.
        N Engl J Med. 2016; 375: 1856-1867https://doi.org/10.1056/NEJMoa1602252
        • El-Khoueiry AB
        • Sangro B
        • Yau T
        • et al.
        Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
        Lancet. 2017; 389: 2492-2502https://doi.org/10.1016/S0140-6736(17)31046-2
        • Schmid P
        • Adams S
        • Rugo HS
        • et al.
        Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer.
        N Engl J Med. 2018; 379: 2108-2121https://doi.org/10.1056/NEJMoa1809615
        • Andre T
        • Shiu KK
        • Kim TW
        • et al.
        Pembrolizumab in microsatellite-instability-high advanced colorectal cancer.
        N Engl J Med. 2020; 383: 2207-2218https://doi.org/10.1056/NEJMoa2017699
        • Overman MJ
        • McDermott R
        • Leach JL
        • et al.
        Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
        Lancet Oncol. 2017; 18: 1182-1191https://doi.org/10.1016/S1470-2045(17)30422-9
        • Wanchoo R
        • Karam S
        • Uppal NN
        • et al.
        Adverse renal effects of immune checkpoint inhibitors: a narrative review.
        Am J Nephrol. 2017; 45: 160-169https://doi.org/10.1159/000455014
        • Herrmann SM
        • Alexander MP
        • Romero MF
        • Zand L
        Renal tubular acidosis and immune checkpoint inhibitor therapy: an immune-related adverse event of PD-1 inhibitor–a report of 3 cases.
        Kidney Med. 2020; 2: 657-662https://doi.org/10.1016/j.xkme.2020.05.015
        • Girotra M
        • Hansen A
        • Farooki A
        • et al.
        The Current Understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management.
        JNCI Cancer Spectr. 2018; 2 (pky021)https://doi.org/10.1093/jncics/pky021
        • Takeno A
        • Yamamoto M
        • Morita M
        • et al.
        Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report.
        BMC Endocr Disord. 2019; 19: 25https://doi.org/10.1186/s12902-019-0335-x
        • Trainer H
        • Hulse P
        • Higham CE
        • Trainer P
        • Lorigan P
        Hyponatraemia secondary to nivolumab-induced primary adrenal failure.
        Endocrinol Diabetes Metab Case Rep. 2016; 2016https://doi.org/10.1530/EDM-16-0108
        • Hong AR
        • Yoon JH
        • Kim HK
        • Kang HC
        Immune Checkpoint inhibitor-induced diabetic ketoacidosis: a report of four cases and literature review.
        Front Endocrinol (Lausanne). 2020; 11: 14https://doi.org/10.3389/fendo.2020.00014
        • Yun K
        • Daniels G
        • Gold K
        • McCowen K
        • Patel SP
        Rapid onset type 1 diabetes with anti-PD-1 directed therapy.
        Oncotarget. 2020; 11: 2740-2746https://doi.org/10.18632/oncotarget.27665
        • Dudley JC
        • Lin MT
        • Le DT
        • Eshleman JR
        Microsatellite instability as a biomarker for PD-1 blockade.
        Clin Cancer Res. 2016; 22: 813-820https://doi.org/10.1158/1078-0432.CCR-15-1678
        • Le DT
        • Durham JN
        • Smith KN
        • et al.
        Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
        Science. 2017; 357: 409-413https://doi.org/10.1126/science.aan6733
        • Marabelle A
        • Le DT
        • Ascierto PA
        • et al.
        Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study.
        J Clin Oncol. 2020; 38: 1-10https://doi.org/10.1200/JCO.19.02105
        • Pederson K
        • Foster N
        • Overman MJ
        • et al.
        ZEBRA: an ACCRU/IRCI multicenter phase 2 study of pembrolizumab in patients with advanced small bowel adenocarcinoma (SBA).
        Ann Oncol. 2019; 30: IV128